Celcuity's Gedatolisib Phase 3 Trial Achieves Primary Endpoint in PIK3CA Mutant Breast Cancer
CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.8× avg).
Summary
Celcuity reported positive Phase 3 trial results for gedatolisib in PIK3CA mutant breast cancer, showing significant improvement in progression-free survival and paving the way for an sNDA submission.
Key Events · Product Development and Regulatory · CELC
-
Positive Phase 3 Trial Results
The PIK3CA mutant cohort of the VIKTORIA-1 trial for gedatolisib achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care.
-
Expanded Market Potential
This success in the PIK3CA mutant population significantly broadens the addressable market for gedatolisib, complementing the existing FDA Priority Review for the PIK3CA wild-type cohort.
-
Planned sNDA Submission
Celcuity intends to submit these positive data to the FDA as a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting.
-
Favorable Safety Profile
Both gedatolisib regimens were generally well tolerated with manageable safety profiles and no new safety signals.
Analysis · CELC · Industrial Applications And Services
Celcuity Inc. announced highly positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib. The drug demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both triplet and doublet regimens, with a manageable safety profile. This success significantly expands the potential market for gedatolisib, building on the existing FDA Priority Review for the PIK3CA wild-type cohort. The company plans to submit these data for a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting, marking a critical step towards broader commercialization and addressing a significant unmet medical need in advanced breast cancer.
At the time of this filing, CELC was trading at $140.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $9.51 to $129.09. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.